Share of novel drug approvals using expedited programs
Percentage of novel therapies approved through one or more expedited regulatory review pathways.
Unit Percent Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Every record
All records
1 record · 1 region · 2024
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 | FDA | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Share of novel drug approvals using expedited programs. Retrieved from https://statorigin.org/indicators/share-of-novel-drug-approvals-using-expedited-programs